ESPEROCT Trademark

Trademark Overview

On Thursday, July 24, 2014, a trademark application was filed for ESPEROCT with the United States Patent and Trademark Office. The USPTO has given the ESPEROCT trademark a serial number of 79152765. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Tuesday, January 19, 2021. This trademark is owned by Novo Nordisk Health Care AG. The ESPEROCT trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for hemostasis management
esperoct

General Information

Serial Number79152765
Word MarkESPEROCT
Filing DateThursday, July 24, 2014
Status706 - SECTION 71 ACCEPTED
Status DateTuesday, January 19, 2021
Registration Number4697829
Registration DateTuesday, March 10, 2015
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 23, 2014

Trademark Statements

Goods and ServicesPharmaceutical preparations for hemostasis management

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 6, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameNovo Nordisk Health Care AG
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressCH
Party NameNovo Nordisk Health Care AG
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCH
Party NameNovo Nordisk Health Care AG
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCH

Trademark Events

Event DateEvent Description
Tuesday, December 23, 2014PUBLISHED FOR OPPOSITION
Thursday, October 2, 2014SN ASSIGNED FOR SECT 66A APPL FROM IB
Monday, October 6, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 10, 2014APPLICATION FILING RECEIPT MAILED
Thursday, November 6, 2014ASSIGNED TO EXAMINER
Wednesday, November 12, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 3, 2014NOTICE OF PUBLICATION
Wednesday, December 3, 2014NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, December 3, 2014NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Friday, December 19, 2014NOTIFICATION PROCESSED BY IB
Tuesday, March 10, 2015REGISTERED-PRINCIPAL REGISTER
Thursday, April 9, 2015GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Wednesday, May 20, 2015FINAL DISPOSITION PROCESSED
Wednesday, May 20, 2015FINAL DISPOSITION NOTICE SENT TO IB
Friday, June 5, 2015NOTIFICATION PROCESSED BY IB
Wednesday, September 30, 2020TEAS SECTION 71 RECEIVED
Friday, January 8, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, January 20, 2021NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Tuesday, January 19, 2021REGISTERED-SEC.71 ACCEPTED
Friday, August 6, 2021CHANGE OF NAME/ADDRESS REC'D FROM IB
Sunday, March 10, 2024COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Thursday, May 2, 2024INTERNATIONAL REGISTRATION RENEWED
Saturday, December 4, 2021NEW REPRESENTATIVE AT IB RECEIVED
Sunday, November 21, 2021NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

esperoct management hemostasis preparations pharmaceutical